Sort
15,842 grants matching “pancreatic cancer”
Development of a protein drug for pancreatic cancer treatment
$999,780Zhi-Ren Liu · Proda Biotech, Llc · R42 · FY2019 · CA
A Prognostic Blood Test to Monitor Pancreatic Cancer Treatment by MiRNA Profiling
$999,597Ravi Saraf · Vajra Instruments, Inc. · R44 · FY2019 · CA
A Prognostic Blood Test to Monitor Pancreatic Cancer Treatment by MiRNA Profiling
$999,597Ravi Saraf · Vajra Instruments, Inc. · R44 · FY2018 · CA
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes
$999,480Ward Peterson · Symberix, Inc. · R44 · FY2020 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments
$998,807Michael H Cardone · Eutropics Pharmaceuticals, Inc. · R44 · FY2017 · CA
MOUSE CANCER MODELS VIA TGF-BETA RII LOSS
$997,931Vanderbilt University · U01 · FY2002 · CA
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
$997,515Valerie Humblet · Collagen Medical, Llc · R44 · FY2016 · CA
Development of novel therapeutics for cancer cachexia
$997,245Scott Matthew Ebert · Emmyon, Inc. · R44 · FY2024 · CA
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing
$997,116Paul A Scheet · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial
$996,940Lynn Kirkpatrick · Prolx Pharmaceuticals Corporation · R44 · FY2006 · CA
Identifying Metabolic Dependencies of Pancreatic Cancers
$996,661Alec Kimmelman · New York University School Of Medicine · R35 · FY2023 · CA
Identifying Metabolic Dependencies of Pancreatic Cancers
$996,661Alec Kimmelman · New York University School Of Medicine · R35 · FY2022 · CA
Recombination and Regulation
$996,412Jeffrey Strathern · Basic Sciences · Z01 · FY2007 · CA
Clinical Validation Center for Early Detection of Pancreatic Cancer
$996,338Anirban Maitra · University Of Tx Md Anderson Can Ctr · U01 · FY2023 · CA
Molecular, Cellular, and Tissue Characterization Unit
$996,148William E Gillanders · Washington University · U2C · FY2018 · CA
PNNL Proteome Characterization Center
$995,930Tao Liu · Battelle Pacific Northwest Laboratories · U24 · FY2019 · CA
Development of TIMP-2 derivatives or strategies as biologic therapies for cancer
$995,769William Stetler-Stevenson · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial
$995,448Lynn Kirkpatrick · Prolx Pharmaceuticals Corporation · R44 · FY2007 · CA
Gene expression and regulation in endocrine cancers
$995,246Electron Kebebew · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$995,112Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
DECODE: Diagnostic Excellence Center on Diagnostic Error
$994,129Ramin Khorasani · Brigham And Women'S Hospital · R18 · FY2023 · HS
DECODE: Diagnostic Excellence Center on Diagnostic Error
$994,128Ramin Khorasani · Brigham And Women'S Hospital · R18 · FY2025 · HS
DECODE: Diagnostic Excellence Center on Diagnostic Error
$992,942Ramin Khorasani · Brigham And Women'S Hospital · R18 · FY2022 · HS
Molecular, Cellular, and Tissue Characterization Unit
$992,570William E Gillanders · Washington University · U2C · FY2020 · CA
Robust Predictor of Breast Cancer Risk
$991,797Harry Ostrer · Morgan And Mendel Genomics, Inc. · R42 · FY2020 · CA